Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04
Opportunity Score
Why this score?
Opportunity
65 / 100
Complexity
20 / 100
Risk factors
Open-house contracts automatically cease if a competitive discount contract for Denosumab is concluded at federal or st...
Incorrect submission (e.g., missing signatures, not meeting format requirements) may delay contract start.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Supply of Denosumab (ATC M05BX04) pharmaceuticals.
- Conclude non-exclusive discount agreements with AOK Bayern under §130a Abs. 8 SGB V.
Show full summary
Open-house model for non-exclusive discount agreements on Denosumab (ATC M05BX04) with AOK Bayern. All qualifying pharmaceutical companies can join on identical terms. Contract runs from 01.11.2024 to 31.10.2026, with possible earlier termination if a competitive discount contract comes into effect. No selection or award criteria – everyone who meets eligibility gets a contract.
Risks
Open-house contracts automatically cease if a competitive discount contract for Denosumab is concluded at federal or st...
Incorrect submission (e.g., missing signatures, not meeting format requirements) may delay contract start.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Tenderer must be a pharmaceutical company (pharmazeutischer Unternehmer).
Administrative
- Submit signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
- Submit signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04
Non-exclusive discount agreements for Denosumab. All interested pharmaceutical companies that meet the eligibility criteria can sign identical contracts. Contracts can be concluded anytime until 05.09.2026. Place of performance: Bayern (DE212).
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 16 Sep 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 557186-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
65 / 100
Complexity
20 / 100
Risk factors
Open-house contracts automatically cease if a competitive discount contract for Denosumab is concluded at federal or st...
Incorrect submission (e.g., missing signatures, not meeting format requirements) may delay contract start.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications